References on the Administration of Agents to Immunodeficient Mice Using ALZET^® Osmotic Pumps

Q0966 Asuthkar,S., Nalla,A.K., Gondi,C.S., Dinh,D.H., Gujrati,M., Mohanam,S., Rao,J.S. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9 - mediated EMT. NEURO-ONCOLOGY 2011; 13(-10-):1059-1073. >>> Plasmid, MMP-9; CSF/CNS; Mice (nude); 2001; 1 week; Controls received mp w/ scrambled vector; animal info (nude);.

Q1024 Daigle,S.R., Olhava,E.J., Therkelsen,C.A., Majer,C.R., Sneeringer,C.J., Song,J., Johnston,L.D., Scott,M.P., Smith,J.J., Xiao,Y.H., Jin,L., Kuntz,K.W., Chesworth,R., Moyer,M.P., Bernt,K.M., Tseng,J.C., Kung,A.L., Armstrong,S.A., Copeland,R.A., Richon,V.M., Pollock,R.M. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. CANCER CELL 2011; 20(-1-):53-65. >>> EPZ004777; Ethanol; water; PEG 300; SC; Mice (nude); 2001; 6, 14 days; Controls received no pump implant; animal info (wks old, nu/nu, female, C57BL/6, 8 wks old); cancer (mixed lineage leukemia); enzyme inhibitor (histone methyltransferase, DOT1L); 10% ethanol used; 50% PEG300 used; pumps replaced after 1 week; "Osmotic pumps were replaced after one week. Irritation caused by compound precipitation was observed in the 100 and 150 mg/ml dose groups, precluding additional pump replacements." pg 63; "Despite the limited 14 day duration of EPZ004777 exposure achieved, we observed a dose-dependent and statistically significant increase in median survival" pg 58.

Q0801 Fujisawa,T., Nakashima,H., Nakajima,A., Joshi,B.H., Puri,R.K. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. International Journal of Cancer 2011; 128(-5-):1221-1231. >>> Interleukin-13-Pseudomonas exotoxin, recomb.; IP; Mice (nude); 14 days; Animal info (nu/nu, 5-6 wks old); comparison of IP injections vs IP mp; IL-13-PE is a recombinant immunotoxin; "Mice receiving continuous IL-13-PE exhibited better tumor response compared to bolus administration" pg 1224.

Q1108 Gupta,R., Nalla,A.K., Gogineni,V.R., Chetty,C., Bhoopathi,P., Klopfenstein,J.D., Tsung,A.J., Mohanam,S., Rao,J.S. uPAR/Cathepsin B Overexpression Reverse Angiogenesis by Rescuing FAK Phosphorylation in uPAR/Cathepsin B Down Regulated Meningioma. PLoS One 2011; 6(-2-):U298-U308. >>> Plasmid, pUC, pU2, FluPAR/Cathepsin B; Mice (nude); ; Controls received mp w/ control plasmid pSV; animal info (athymic, nu/nu, female, 5-7 wks old); cancer (meningioma).

Q1161 Kesanakurti,D., Chetty,C., Bhoopathi,P., Lakka,S.S., Gorantla,B., Tsung,A.J., Rao,J.S. Suppression of MMP-2 Attenuates TNF-alpha Induced NF-kappaB Activation and Leads to JNK Mediated Cell Death in Glioma. PLoS One 2011; 6(-5-):U239-U252. >>> RNA, small interfering, MMP-2; CSF/CNS (intratumorally); Mice (nude); 2004; ; Animal info (athymic, female, nu/nu, 4-6 wks old); cancer (glioma); tissue perfusion (intratumorally); MMP2siRNA;.

Q1166 Kim,J., Koyanagi,T., Mochly-Rosen,D. PKCdelta Activation Mediates Angiogenesis via NADPH Oxidase Activity in PC-3 Prostate Cancer Cells. PROSTATE 2011; 71(-9-):946-954. >>> V1-1, delta; RACK, delta omega; Saline; Mice (nude); 2001; 4 weeks; Controls received mp w/ TAT carrier peptide; animal info (6 wks old, male, nu/nu); peptides; pumps replaced after 2 weeks; cancer (prostate); half-life, 2 weeks in the pump (p. 947); deltaV1-1 is a PKC delta-selective inhibitor; delta gamma RACK is a PKC delta selective activator.

Q1171 Kita,A., Nakahara,T., Yamanaka,K., Nakano,K., Nakata,M., Mori,M., Kaneko,N., Koutoku,H., Izumisawa,N., Sasamata,M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. LEUKEMIA RESEARCH 2011; 35(-6-):787-792. >>> YM155; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (BALB/c, nu/nu, male, 5 wks old); cancer (lymphoma).

Q0709 Kurio,N., Shimo,T., Fukazawa,T., Takaoka,M., Okui,T., Hassan,N.M.M., Honami,T., Hatakeyama,S., Ikeda,M., Naomoto,Y., Sasaki,A. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAX and IGF-IR in vitro and in vivo. Experimental Cell Research 2011; 317(-8-):1134-1146. >>> Parathyroid hormone-related peptide (1-34); Saline, physiological; cysteine, L-; SC; Mice (nude); 1007D; ; Controls received mp w/ vehicle; animal info (5 wls old, male, BALB/c); cancer.

Q1219 Martiniova,L., Lu,J., Chiang,J., Bernardo,M., Lonser,R., Zhuang,Z.P., Pacak,K. Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS One 2011; 6(-2-):U67-U74. >>> LB1; PBS; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; animal info (female, athymic, NCr-nu, 6-10 wks old); cancer; enzyme inhibitor (serine/threonine protein phosphatase 2A, PP2A); chemotherapeutic.

Q0705 Ren,P.G., Irani,A., Huang,Z.N., Ma,T., Biswal,S., Goodman,S.B. Continuous Infusion of UHMWPE Particles Induces Increased Bone Macrophages and Osteolysis. Clinical Orthopaedics and Related Research 2011; 469(-1-):113-122. >>> Polyethylene particles, UHMWPE; Saline; Bone (femur); Mice (nude); 2006; 3 weeks; Controls received mp w/ vehicle; animal info (12 wks old, male); post op. care (buprenorphine), pg 115; Fig 1A, diagram of pump and catheter placement; pump connected to titanium rod; bioluminescence; Ultra High Molecular Weight Polyethylene (UHMWPE).

Q0907 Saghafi,N., Lam,D.K., Schmidt,B.L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neuroscience Letters 2011; 488(-3-):247-251. >>> WIN55,212-2; ACEA; AM1241; DMSO; water; SC; Mice (nude); 2002; 2 weeks; Animal info (Foxn1 nu, athymic, 4-5 wks old, 20-25 g); cancer (oral); behavioral testing (mechanical allodynia); 50% DMSO used; wound clips used; pain.

Q0977 Blaya,B., Nicolau-Galmes,F., Jangi,S.M., Ortega-Martinez,I., onso-Tejerina,E., Burgos-Bretones,J., Perez-Yarza,G., Asumendi,A., Boyano,M.D. Histamine and Histamine Receptor Antagonists in Cancer Biology. Inflammation&Allergy Drug Targets 2010; 9(-3-):146-157. >>> Terfenadine; DMSO; PBS; SC; Mice (nude); ; Controls received mp w/ vehicle; animal info (C57BL/6, syngenic); cancer; Fig. 6, image of pump implanted in nude mice.

Q0582 Carcaboso,A.M., Elmeliegy,M.A., Shen,J., Juel,S.J., Zhang,Z.W.M., Calabrese,C., Tracey,L., Waters,C.M., Stewart,C.F. Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research 2010; 70(-11-):4499-4508. >>> Topotecan; Water, sterile; SC; Mice (nude); 2001D; 8-12 hours; Animal info (CD1, nude); cancer (glioma).

Q0109 Chambliss,K.L., Wu,Q.A., Oltmann,S., Konaniah,E.S., Umetani,M., Korach,K.S., Thomas,G.D., Mineo,C., Yuhanna,I.S., Kim,S.H., Madak-Erdogan,Z., Maggi,A., Dineen,S.P., Roland,C.L., Hui,D.Y., Brekken,R.A., Katzenellenbogen,J.A., Katzenellenbogen,B.S., Shaul,P.W. Non-nuclear estrogen receptor-alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. Journal of Clinical Investigation 2010; 120(-7-):2319-2330. >>> Estradiol; estrogen-dendrimer conjugate; IP; Mice (nude); 3, 7 weeks; 72 hours; Controls received mp w/ empty dendrimer; cardiovascular; cancer (breast); animal info (female, ERE-Luc reporter, 10-13 weeks old; Ex3aERKO, 8-9 weeks old; C57BL/6 Apoe-/-, 6 weeks old; SCID, 8 weeks old); functionality of mp verified by serum agent levels; replacement therapy (ovariectomy; pumps replaced after 28 days); long-term study; photon recording with light emission tomography (LET) system with a CCD camera; Research Diets D10001.

Q1020 Cox,C.D., Garbaccio,R.M. Discovery of Allosteric Inhibitors of Kinesin Spindle Protein (KSP) for the Treatment of Taxane-Refractory Cancer: MK-0731 and Analogs. Anti-Cancer Agents in Medicinal Chemistry 2010; 10(-9-):697-712. >>> MK-0731; IV; Mice (nude); 24 hours; Animal info (naive); dose-response, Fig 12 ; half-life 4-10 hours (p. 710); MK-0731 is a KSP inhibitor (kinesin spindle protein); maximum tolerated dose (MTD) is 12 mg/kg.

Q0111 Demestre,M., Herzberg,J., Holtkamp,N., Hagel,C., Reuss,D., Friedrich,R.E., Kluwe,L., Von Deimling,A., Mautner,V.F., Kurtz,A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. Journal of Neuro-oncology 2010; 98(-1-):11-19. >>> Imatinib mesylate; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (Plexiform neurofibromas); enzyme inhibitor (receptor tyrosine kinase); stress/adverse reaction: (see pg 13) "because of inflammation at the ALZET pump site, four mice of the treatment group had to be discontinued"; animal info (female, athymic nu/nu Balb/c); agent also known as Glivec or Gleevec.

Q0129 Goda,M., Atagi,S., Amitani,K., Hobara,N., Kitamura,Y., Kawasaki,H. Nerve Growth Factor Suppresses Prostate Tumor Growth. JOURNAL OF PHARMACOLOGICAL SCIENCES 2010; 112(-4-):463-466. >>> Nerve growth factor; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ saline; cancer (prostate); animal info (BALB/c, Slc, 5 wks old, nu/nu).

Q0589 Iwasa,T., Okamoto,I., Takezawa,K., Yamanaka,K., Nakahara,T., Kita,A., Koutoku,H., Sasamata,M., Hatashita,E., Yamada,Y., Kuwata,K., Fukuoka,M., Nakagawa,K. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. British Journal of Cancer 2010; 103(-1-):36-42. >>> YM-155; cisplatin; carboplatin; DMSO; IV; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; animal info (male, nude, BALB/cAnNCrj-nu/nu, 5 weeks old); 0.1% DMSO used; cancer.

Q1168 Kioi,M., Vogel,H., Schultz,G., Hoffman,R.M., Harsh,G.R., Brown,J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Journal of Clinical Investigation 2010; 120(-3-):694-705. >>> AMD3100; Mice (nude); 21 days; Animal info (athymic, nu/nu); cancer; "An important feature of our data is that although we completed the drug infusion before the tumors were eradicated, the tumors continued to shrink and did not recur even long after the end of the infusion." pg 702.

Q0402 Kozin,S.V., Kamoun,W.S., Huang,Y.H., Dawson,M.R., Jain,R.K., Duda,D.G. Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. Cancer Research 2010; 70(-14-):5679-5685. >>> AMD3100; IV; Mice (nude); 2 weeks; Animal info (mice athymic NCr/Sed nude (nu/nu) mice, female syngeneic FVB).

Q1180 Kraeber-Bodere,F., Bodet-Milin,C., Niaudet,C., Sai-Maurel,C., Moreau,A., Faivre-Chauvet,A., Thomare,P., Deleris,G., Estieu-Gionnet,K., Bikfalvi,A., Barbet,J., Paris,F. Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigen-Expressing Medullary Thyroid Cancer Xenograft. Journal of Nuclear Medicine 2010; 51(-4-):624-631. >>> CBOP11; SC; Mice (nude); 2004; 25 days; Animal info (10 wks old); cancer; CBOP11 is a cyclopeptidic vascular endothelial growth inhibitor.

Q1194 Laursen,M.B., Pakula,M.M., Gao,S., Fluiter,K., Mook,O.R., Baas,F., Langklaer,N., Wengel,S.L., Wengel,J., Kjems,J., Bramsen,J.B. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Molecular BioSystems 2010; 6(-5-):862-870. >>> RNA, small interfering, unlocked nucleic acid modified; SC; Mice (nude); ; Animal info (NMRI, nu/nu, 8-10 wks old).

Q1201 Lenz,A., Sun,Y., Eichelbaum,E.J., Skelton,W.P., Pi,G., Vesely,D.L. Cardiac hormones eliminate some human squamous lung carcinomas in athymic mice. European Journal of Clinical Investigation 2010; 40(-3-):242-249. >>> Vessel dilator; kaliuretic peptide; atrial natriuretic peptide; long-acting natriuretic peptide; Saline; SC; Mice (nude); 1007D; 28 days; Controls received mp w/ vehicle; animal info (male, athymic, nu/nu, 20 g); peptides; pumps replaced weekly; cancer (lung);.

Q1189 Lo,A.S.Y., Ma,Q.Z., Liu,D.L., Junghans,R.P. Anti-GD3 Chimeric sFv-CD28/T-Cell Receptorζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors. Clinical Cancer Research 2010; 16(-10-):2769-2780. >>> Interleukin-2, recomb.; PBS; albumin, human; SC; Mice (nude); 7 days; Controls received mp w/ vehicle; animal info (8 wks old, female, Balb/C, nu/nu); cancer (melanoma); "These pumps are easily loaded and then placed s.c., minimizing discomfort and handling of the mice as needed for repeated IL2 administration by injection." pg 2777.

Q0617 Martin,S.K., Diamond,P., Williams,S.A., To,L.B., Peet,D.J., Fujii,N., Gronthos,S., Harris,A.L., Zannettino,A.C.W. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica-The Hematology Journal 2010; 95(-5-):776-784. >>> T140; PBS; SC; Mice (nude); ; Postive controls received LP-1 cells stably over-expressing CXCL12; animal info (6 wks old, female, BALB/c); 100 ul sized pump used; T140 is a CXCR4 antagonist; bioluminescence.

Q0206 Masunaga,S., Tano,K., Nakamura,J., Watanabe,M., Kashino,G., Takahashi,A., Tanaka,H., Suzuki,M., Ohnishi,K., Kinashi,Y., Liu,Y., Ohnishi,T., Ono,K. Usefulness of Hexamethylenetetramine as an Adjuvant to Radiation and Cisplatin in the Treatment of Solid Tumors: its Independency of p53 Status. Journal of Radiation Research 2010; 51(-1-):27-35. >>> Uridine, bromodeoxy; hexamethylenetetramine; Saline, physiological; SC; Mice (nude); 2001D; 2001; 7 days; 24 hours; Cancer; toxicology; animal info (6-7 weeks old, female, syngenic, Balb/Ca); labeling of P cells.

P9990 Mercapide,J., Rappa,G., Anzanello,F., King,J., Fodstad,O., Lorico,A. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. International Journal of Cancer 2010; 126(-5-):1206-1215. >>> Cyclophosphamide; CSF/CNS; Mice (nude); ; Controls received mp w/ sterile saline; animal info (6 wks old, female).

P9917 Murray,B.W., Guo,C.X., Piraino,J., Westwick,J.K., Zhang,C., Lamerdin,J., Dagostino,E., Knighton,D., Loi,C.M., Zager,M., Kraynov,E., Popoff,I., Christensen,J.G., Martinez,R., Kephart,S.E., Marakovits,J., Karlicek,S., Bergqvist,S., Smeal,T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-20-):9446-9451. >>> PF-3758309; Mice (nude); 9 days; Dose response; enzyme inhibitor (P21-activated kinsase); animal info (athymic, CRL breed, 6-8 weeks); cancer.

Q0795 Nalla,A.K., Asuthkar,S., Bhoopathi,P., Gujrati,M., Dinh,D.H., Rao,J.S. Suppression of uPAR Retards Radiation-Induced Invasion and Migration Mediated by Integrin beta-1/FAK Signaling in Medulloblastoma. PLoS One 2010; 5(-9-):U240-U255. >>> RNA, small interfering, uPAR; Mice (nude); 2001; 1 week; siRNA is within a plasmid vector (pU vector).

Q1312 Sapra,P., Wang,M.L., Bandaru,R., Zhao,H., Greenberger,L.M., Horak,I.D. Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide. NUCLEOSIDES NUCLEOTIDES&NUCLEIC ACIDS 2010; 29(-2-):97-112. >>> Oligonucleotide, antisense; SC; Mice (nude); 7 days; Controls received mp w/ EZN-3046, scrambled control nucleotide; animal info (4-5 wks old); antisense (EZN-3042); cancer (lymphoma).

Q0095 Schmidt,N.O., Ziu,M., Cargioli,T., Westphal,M., Giese,A., Black,P.M., Carroll,R.S. Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. Translational Oncology 2010; 3(-1-):43-49. >>> Furegrelate; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; tissue perfusion (tumor); functionality of mp verified by residual volume; stress/adverse reaction: (see pg. 46) "hemosiderin deposits"; cancer (glioma); ALZET brain infusion kit used; animal info (Swiss, 4-6 wks old).

Q0341 Verpelli,C., Bertani,G., Cea,V., Patti,M., Bikfalvi,A., Bello,L., Sala,C. Anti-Angiogenic Therapy Induces Integrin-Linked Kinase 1 Up-Regulation in a Mouse Model of Glioblastoma. PLoS One 2010; 5(-10-):U70-U81. >>> PF4-DLR; RNA, small interfering; PBS; SC; CSF/CNS (intrathecal); Mice (nude); 2004; 10, 20 days; Controls received mp w/ vehicle; animal info (6 wks old, nude); peptides; ILK1-siRNA.

P9502 Armaiz-Pena,G.N., Mangala,L.S., Spannuth,W.A., Lin,Y.G., Jennings,N.B., Nick,A.M., Langley,R.R., Schmandt,R., Lutgendorf,S.K., Cole,S.W., Sood,A.K. Estrous Cycle Modulates Ovarian Carcinoma Growth. Clinical Cancer Research 2009; 15(-9-):2971-2978. >>> Estradiol, 17b-; progesterone; megestrol acetate; Cyclodextrin, b-; water; SC; Mice (nude); ; Replacement therapy (ovariectomy); animal info (female, athymic); cancer (ovarian).

P9597 Beauvais,D.M., Ell,B.J., McWhorter,A.R., Rapraeger,A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009; 206(-3-):691-705. >>> Synstatin (82-130); synstatin (94-119); synstatin (92-119); cyclic RGDfv; cyclic RADfv; PBS; DMSO; H2O, double distilled; Mice (nude); 2004; 4 weeks; Controls received mp w/vehicle, or PBS; cancer; peptides; animal info (6-8 wks old, female, athymic, BALB/c); 50% DMSO used.

R0270 Becker,L.C., Bergfeld,W.F., Belsito,D.V., Klaassen,C.D., Marks,JG Jr, Shank,R.C., Slaga,T.J., Snyder,P.W., Cosmetic Ingredient Review Expert, Andersen,F.A. Final Report of the Safety Assessment of Hyaluronic Acid, Potassium Hyaluronate, and Sodium Hyaluronate. INTERNATIONAL JOURNAL OF TOXICOLOGY 2009; 28(-;-):5-67. >>> Hyaluronic acid; Mice (nude); 7, 14 days; Controls received mp w/ PBS; animal info (Balb/c, nu/nu, male).

Q0580 Diamond,P., Labrinidis,A., Martin,S.K., Farrugia,A.N., Gronthos,S., To,L.B., Fujii,N., O'Loughlin,P.D., Evdokiou,A., Zannettino,A.C.W. Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss. Journal of Bone and Mineral Research 2009; 24(-7-):1150-1161. >>> T140; PBS; SC; Mice (nude); 1002; 28 days; Controls received mp w/ vehicle; animal info (4 wks old, female, Balb/c, nude); pumps replaced after 14 days; T140 (also known as 4F-Benzoyl-TE14011) is a CXCR4 inhibitor.

Q0586 Dilda,P.J., Decollogne,S., Weerakoon,L., Norris,M.D., Haber,M., Allen,J.D., Hogg,P.J. Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the Cytosol. Journal of Medicinal Chemistry 2009; 52(-20-):6209-6216. >>> Phenylarsonous acid; PBS; SC; Mice (nude); 1004; ; Controls received mp w/ vehicle; animal info (BalbC, nude, Female 7-9 week old); stability verified in vitro for at least 2 weeks at 4 or 37 degrees C; "There was a small accumulation of connective tissue at the delivery site of the osmotic pump in 7 of the 10 mice at the higher dose of PENAO. This is likely the result of a local inflammatory response triggered by the high concentrations of PENAO at the delivery site." pg 6213; Phenylarsonous acid (PENAO) is a cysteine mimetic analogue of CAO; cancer.

P9606 Harada,H., Itasaka,S., Kizaka-Kondoh,S., Shibuya,K., Morinibu,A., Shinomiya,K., Hiraoka,M. The Akt/mTOR Pathway Assures the Synthesis of HIF-1-alpha Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors. Journal of Biological Chemistry 2009; 284(-8-):5332-5342. >>> Luciferin, D-; glucose, 2-deoxy-D-; PBS; water; SC; Mice (nude); ; Controls received mp/vehicle; cancer; animal info (6 weeks old, male, BALB/c, nu/nu) IVIS-200; bioluminescence.

P9688 Harada,H., Itasaka,S., Zhu,Y., Zeng,L., Xie,X., Morinibu,A., Shinomiya,K., Hiraoka,M. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. British Journal of Cancer 2009; 100(-5-):747-757. >>> Luciferin, D-; PBS; SC; Mice (nude); 1007D; ; Animal info (BALB/c, nu/nu); IVIS-200; bioluminescence.

Q0045 Inbar-Rozensal,D., Castiel,A., Visochek,L., Castel,D., Dantzer,F., Izraeli,S., Cohen-Armon,M. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. BREAST CANCER RESEARCH 2009; 11(-6-):U19-U29. >>> PJ-34; PBS; SC; Mice (nude); 14 days; controls received mp w/ vehicle or no treatment/no mp; enzyme inhibitor (poly-ADP-ribose polymerase); cancer (breast); no stress (R80); animal info (female, CD-1 nu/nu, 5-6 weeks old); "the 14-day treatment with a slow release of PJ-34 did not affect the vitality, growth, development, or any other behavior of the treated mice during the follow-up periods. (p. R80).

Q1136 Inoue,K., Aoi,N., Yamauchi,Y., Sato,T., Suga,H., Eto,H., Kato,H., Tabata,Y., Yoshimura,K. TGF-β(2) is specifically expressed in human dermal papilla cells and modulates hair folliculogenesis. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 2009; 13(-11-12-):4643-4656. >>> SB431542; SC; Mice (nude); 4 weeks; Controls received mp w/ vehicle; animal info (6 wks old, Balb/c); enzyme inhibitor (kinase, TGF-beta type 1 receptor); rate of 0.25 ul/hr.

P9538 Kazi,A., Carie,A., Blaskovich,M.A., Bucher,C., Van,Thai, Moulder,S., Peng,H., Carrico,D., Pusateri,E., Pledger,W.J., Berndt,N., Hamilton,A., Sebti,S.M. Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy. MOLECULAR AND CELLULAR BIOLOGY 2009; 29(-8-):2254-2263. >>> GGTI-2418; Polyethylene glycol; DMSO; SC; Mice (nude); 14 days; Controls received mp w/vehicle; cancer (breast); 20% DMSO used; enzyme inhibitor (geranylgeranyltransferase I).

P9670 Lee,J.W., Shahzad,M.M.K., Lin,Y.G., rmaiz-Pena,G., Mangala,L.S., Han,H.D., Kim,H.S., Nam,E.J., Jennings,N.B., Halder,J., Nick,A.M., Stone,R.L., Lu,C.H., Lutgendorf,S.K., Cole,S.W., Lokshin,A.E., Sood,A.K. Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma. Clinical Cancer Research 2009; 15(-8-):2695-2702. >>> Propranolol hydrochloride, S-; SC; Mice (nude); 2004; ; Controls received mp w/ PBS; no stress (see pg. 2697) "no significant complications"; cancer (ovarian); animal info (female, athymic, Ncr-nu).

P9629 Minematsu,T., Iwai,M., Sugimoto,K., Shirai,N., Nakahara,T., Usui,T., Kamimura,H. Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9- dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells. Drug Metabolism and Disposition 2009; 37(-3-):619-628. >>> YM155, 14C-; SC; Mice (nude); 1003D; 3 days; Cancer; animal info (5 wks old, male, Balb/c-nu/nu); "YM155 showed high distribution to tumor tissues after continuous administration to nude mice bearing PC-3 tumors." pg 627.

P9897 Onimaru,M., Yonemitsu,Y., Fujii,T., Tanii,M., Nakano,T., Nakagawa,K., Kohno,R., Hasegawa,M., Nishikawa,S., Sueishi,K. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. American Journal of Physiology-Heart and Circulatory Physiology 2009; 297(-5-):H1685-H1696. >>> AFL-4; IP; Mice (nude); 1007D; 7 days; Controls received mp w/control antibody; animal info (male, C57BL/6J, 6 wks old, nu; BALB/C, nu, 5 wks old); AFL-4 is a murine VEGFR3-specific neutralizing antibody.

Q0238 Richards,A., McGeechan,K., Niknam,M., Salomon,R., Kurek,C., Dong,Q.H., Patel,M.I. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?. ANZ JOURNAL OF SURGERY 2009; 79(-9-):641-647. >>> Celecoxib; DMSO; ethanol; water; SC; Mice (nude); 2004; 8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced after 28 days; stress/adverse reaction (see pg. 646 "local skin dryness and erosion"); enzyme inhibitor (COX-2); cancer (prostate); incorrectly stated pump model 2400; 50% DMSO used; 15% ethanol used.

P9819 Savai,R., Langheinrich,A.C., Schermuly,R.T., Pullamsetti,S.S., Dumitrascu,R., Traupe,H., Rau,W.S., Seeger,W., Grimminger,F., Banat,A. Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. NEOPLASIA 2009; 11(-1-):48-56. >>> Bevacizumab; IV (jugular); Mice (nude); 2002; 14 days; Controls received mp w/ distilled water; animal info (female, C57BL/6, 5-7 wks old, BALB/c, nu/nu, 7-8 wks old); pump implated IP; bevacizumab is a anti-VEGF antibody; "This delivery (using ALZET pumps) mimics local delivery of antivascular agents and can be used effectively alone or in combination with cytotoxic chemotherapy for site-specific drug delivery for lung cancer treatment. As expected, continuous infusion of bevacizumab decreased lung tumor volume and tumor perfusion, with an added survival advantage compared to the untreated group." pg 55; cancer (lung); antibody.

P9478 Schauff,A.K., Kim,E.L., Leppert,J., Nadrowitz,R., Wuestenberg,R., Brockmann,M.A., Giese,A. Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. Journal of Neuro-oncology 2009; 91(-3-):241-249. >>> Furegrelate; CSF/CNS (intratumoral); Mice (nude); 1002; 14 days; Controls were untreated; enzyme inhibitor (thromboxane synthase TXSA); cancer (glioma); tissue perfusion (tumor); ALZET brain infusion kit 3 used; animal info (NMRI).

P9708 Schmidt,N.O., Koeder,D., Messing,M., Mueller,F.J., Aboody,K.S., Kim,S.U., Black,P.M., Carroll,R.S., Westphal,M., Lamszus,K. Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Research 2009; 1268(-;-):24-37. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice (nude); 2004; ; Controls received mp w/PBS; animal info (6 wks old).

P9727 Skipper,J.B., McNally,L.R., Rosenthal,E.L., Wang,W.Q., Buchsbaum,D.J. In vivo Efficacy of Marimastat and Chemoradiation in Head and Neck Cancer Xenografts. ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES 2009; 71(-1-):1-5. >>> Marimastat; DMSO; SC; Mice (nude); 2002; 14 days; Controls received mp w/vehicle; cancer; animal info (3 mo old, female).

P9511 Uchibori,R., Okada,T., Ito,T., Urabe,M., Mizukami,H., Kume,A., Ozawa,K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. JOURNAL OF GENE MEDICINE 2009; 11(-5-):373-381. >>> Ganciclovir; IP; Mice (nude); 28 days; Controls received mp w/ PBS; animal info (6 wks old, male, Balb/c, nu/nu); gene therapy.

P9364 Vanamala,S.K., Gopinath,S., Gondi,C.S., Rao,J.S. Effect of human umbilical cord blood cells on Ang-II-induced hypertrophy in mice. Biochemical and Biophysical Research Communications 2009; 386(-2-):386-391. >>> Angiotensin II; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; animal info (female, 8 wks old); dose (400 ng/kg/min).

Q0625 Yoon,H., Kim,D.J., Ahn,E.H., Gellert,G.C., Shay,J.W., Ahn,C.H., Lee,Y.B. Antitumor Activity of a Novel Antisense Oligonucleotide Against Akt1. Journal of Cellular Biochemistry 2009; 108(-4-):832-838. >>> Oligonucleotide, antisense; IP; Mice (nude); 1002; 14 days; Animal info (nu/nu); bioluminescence.

P9286 Ciceroni,C., Arcella,A., Mosillo,P., Battaglia,G., Mastrantoni,E., Oliva,M.A., Carpinelli,G., Santoro,F., Sale,P., Ricci-Vitiani,L., De Maria,R., Pallini,R., Giangaspero,F., Nicoletti,F., Melchiorri,D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. Neuropharmacology 2008; 55(-4-):568-576. >>> LY379268; LY341495; SC; Mice (nude); 3 months; Controls received mp w/ saline; long-term study; pumps replaced every 15-28 days; cancer (brain, glioma); MRI; animal info (male, CD-1, nude); mGlu3 receptor-agonist, antagonist.

P8818 Conigliaro,A., Colletti,M., Cicchini,C., Guerra,M.T., Manfredini,R., Zini,R., Bordoni,V., Siepi,F., Leopizzi,M., Tripodi,M., Amicone,L. Isolation and characterization of a murine resident liver stem cell. CELL DEATH AND DIFFERENTIATION 2008; 15(-1-):123-133. >>> Fibroblast growth factor, bovine; Heparin; SC; Mice (nude); 10 days; Peptides.

P9210 Cox,C.D., Coleman,P.J., Breslin,M.J., Whitman,D.B., Garbaccio,R.M., Fraley,M.E., Buser,C.A., Walsh,E.S., Hamilton,K., Schaber,M.D., Lobell,R.B., Tao,W., Davide,J.P., Diehl,R.E., Abrams,M.T., South,V.J., Huber,H.E., Torrent,M., Prueksaritanont,T., Li,C., Slaughter,D.E., Mahan,E., Fernandez-Metzler,C., Yan,Y., Kuo,L.C., Kohl,N.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4- yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1- carboxamide (MK-0731) for the treatment of taxane-refractory cancer. Journal of Medicinal Chemistry 2008; 51(-14-):4239-4252. >>> MK-0731; piperidine analog, trans-fluoro-methylamine; Water; HCl; SC; Mice (nude); 2001D; 22 hours; Controls received mp w/ vehicle; dose-response (fig. 1); half-life (p.4246) 1 hour in rats; cancer (ovarian carcinoma); animal info (female, Crl: Nu/Nu-nuBR, 8-12 wks old, 25-30 g.); Kinesin spindle protein inhibitor; "subcutaneously implanted ALZET Osmotic Pumps were used for their ability to mimic a continuous iv infusion over the 22h course of the experiment... This protocol provides the best oppotunity to maintain plasma exposure for the required length of time without exposing the patient to high levels of drug following a bolus infusion." (p. 4243).

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8817 Dings,R.P.M., Van Laar,E.S., Webber,J., Zhang,Y., Griffin,R.J., Waters,S.J., MacDonald,J.R., Mayo,K.H. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 2008; 265(-2-):270-280. >>> Anginex; anginex topomimetic 0118; SC; Mice (nude); 28 days; Cancer (ovarian carcinoma); animal info (female, athymic nu/nu, 5-6 wks old); antiangiogenic.

P9170 Eichelbaum,E.J., Sun,Y., Alli,A.A., Gower,WR Jr, Vesely,D.L. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice. European Journal of Clinical Investigation 2008; 38(-8-):562-570. >>> Natriuretic peptide, long acting; atrial natriuretic peptide; vessel dilator peptide; kaliuretic peptide; urodilatin; Saline; SC; Mice (nude); 1007D; 4 weeks; Controls received mp w/ vehicle; cancer (small cell lung); peptides; animal info (nu/nu, athymic); urodilatin is a kidney hormone.

P9285 Feldmann,G., Fendrich,V., McGovern,K., Bedja,D., Bisht,S., Alvarez,H., Koorstra,J.B.M., Habbe,N., Karikari,C., Mullendore,M., Gabrielson,K.L., Sharma,R., Matsui,W., Maitra,A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. MOLECULAR CANCER THERAPEUTICS 2008; 7(-9-):2725-2735. >>> IPI-269609; Cyclodextrin, 2-hydroxypropyl-b-; water, sterile; SC; Mice (nude); 2002; 6 weeks; 5, 7 days; Controls received mp w/ vehicle; comparison of daily PO vs. mp; pumps replaced every 2 wks; no stress (see pg. 2734); cancer (pancreatic); multiple pumps per animal (2); animal info (male, athymic CD1 nu/nu, 6-12 wks old); 30% cyclodextrin; Hedgehog inhibitor; "at the applied doses there were no signs of toxicity, weight loss, or other signs of adverse events in mice during the described treatment periods." (p. 2734).

P9111 Gao,Y., Wu,X., Terauchi,M., Li,J.Y., Grassi,F., Galley,S., Yang,X., Weitzmann,M.N., Pacifici,R. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metabolism 2008; 8(-2-):132-145. >>> Parathyroid hormone (1-34), human; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; peptides; animal info (female, C57BL/6, 10 wks old, wt, nu/nu).

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

P9114 Iwasa,T., Okamoto,I., Suzuki,M., Nakahara,T., Yamanaka,K., Hatashita,E., Yamada,Y., Fukuoka,M., Ono,K., Nakagawa,K. Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines. Clinical Cancer Research 2008; 14(-20-):6496-6504. >>> YM155; Saline; Mice (nude); 1003D; 7 days; Controls received mp w/ vehicle; cancer (lung); animal info (BALB/c, athymic, 6 wks old, female); YM155 is a small inhibitor of survivin expression.

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; long-term study; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P9143 Kim,J.W., Choi,Y.L., Vallentin,A., Hunrichs,B.S., Hellerstein,M.K., Peehl,D.M., Mochly-Rosen,D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Research 2008; 68(-16-):6831-6839. >>> TAT (47-57); IIV5-3, beta-; Saline; Mice (nude); 2001; 5 weeks; Controls received mp w/ vehicle or TAT (47-57); pumps replaced every 2 weeks; half-life (p. 6832) ~ 2 wks; enzyme inhibitor (PKC betaII, protein kinase C); animal info (6 wks old, male).

P9680 Martens,T., Laabs,Y., Guenther,H.S., Kemming,D., Zhu,Z.P., Witte,L., Hagel,C., Westphal,M., Lamszus,K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clinical Cancer Research 2008; 14(-17-):5447-5458. >>> Cetuximab; CSF/CNS (intratumoral); Mice (nude); 2004; ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (NMRI- nu/nu, 6-8 wks old); cetuximab is a monoclonal antibody against EGFR.

P9728 Mersereau,J.E., Levy,N., Staub,R.E., Baggett,S., Zogric,T., Chow,S., Ricke,W.A., Tagliaferri,M., Cohen,I., Bjeldanes,L.F., Leitman,D.C. Liquiritigenin is a plant-derived highly selective estrogen receptor-beta agonist. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2008; 283(-1-2-):49-57. >>> Liquiritigenin; estradiol; SC; Mice (nude); 1 month; Controls received mp w/vehicle; cancer (breast); implies using 2ML4 pump (2.5ul/h); Liquiritigenin is a ER-beta selective compound extracted from the root of G. uralensis.

P9278 Nasr,R., Guillemin,M.C., Ferhi,O., Soilihi,H., Peres,L., Berthier,C., Rousselot,P., Robledo-Sarmiento,M., Lallemand-Breitenbach,V., Gourmel,B., Vitoux,D., Pandolfi,P.P., Rochette-Egly,C., Zhu,J., The,H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine 2008; 14(-12-):1333-1342. >>> Bortezomib; cyclic AMP; H89; SC; Mice (nude); mice (transgenic); 1, 3, 6, 7 days; Controls received no treatment; enzyme inhibitor (PKA); cancer (acute promyelocytic leukemia); animal info (nude, PLZF-RARA-RARA-PLZF; PML-RARA5873A Tg); Bortezomib is a proteasome inhibitor.

P9129 Rodriguez,R., Hansen,L.T., Phear,G., Scorah,J., Spang-Thomsen,M., Cox,A., Helleday,T., Meuth,M. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clinical Cancer Research 2008; 14(-17-):5476-5483. >>> Thymidine; Saline; SC; Mice (nude); 2001; ; Controls received vehicle IP; animal info (male, 6 wks old, athymic, nu/nu).

P8791 Song,P.F., Sekhon,H.S., Fu,X.W., Maier,M., Jia,Y.B., Duan,J., Proskosil,B.J., Gravett,C., Lindstrom,J., Mark,G.P., Saha,S., Spindel,E.R. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Research 2008; 68(-12-):4693-4700. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (lung carcinoma); animal info (male, nu/nu); 50% DMSO; M3 mAChR antagonist.

P9469 Yano,A., Tsutsumi,S., Soga,S., Lee,M.J., Trepel,J., Osada,H., Neckers,L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-40-):15541-15546. >>> Reveromycin A; SC; Mice (nude); 2004; 2.5 weeks; Controls received mp IP DMSO injections 2x/week; cancer (prostate carcinoma); animal info (male, nu/nu, 6 wks old); osteoclast-specific apoptosis-inducer.

P9077 Ye,L., Lewis-Russell,J.M., Sanders,A.J., Kynaston,H., Jiang,W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 2008; 26(-2-):190-197. >>> Hepatocyte growth factor, recomb. human; NK4, recomb. human; SC; Mice (nude); 2004; 4 weeks; Cancer (prostate); animal info (athymic, male, CD-1, 4-6 wks old).

P8066 Bielinska,M., Seehra,A., Toppari,J., Heikinheimo,M., Wilson,D.B. GATA-4 is required for sex steroidogenic cell development in the fetal mouse. Developmental Dynamics 2007; 236(-1-):203-213. >>> Luteinizing HRH, D-Trple; SC; Mice (nude); 3 weeks; Replacement therapy (gonadectomy); peptides; animal info (female, NU/J, chimeric teratoma).

Q0501 Donawho,C.K., Luo,Y., Luo,Y.P., Penning,T.D., Bauch,J.L., Bouska,J.J., Bontcheva-Diaz,V.D., Cox,B.F., DeWeese,T.L., Dillehay,L.E., Ferguson,D.C., Ghoreishi-Haack,N.S., Grimm,D.R., Guan,R., Han,E.K., Holley-Shanks,R.R., Hristov,B., Idler,K.B., Jarvis,K., Johnson,E.F., Kleinberg,L.R., Klinghofer,V., Lasko,L.M., Liu,X.S., Marsh,K.C., McGonigal,T.P., Meulbroek,J.A., Olson,A.M., Palma,J.P., Rodriguez,L.E., Shi,Y., Stavropoulos,J.A., Tsurutani,A.C., Zhu,G.D., Rosenberg,S.H., Giranda,V.L., Frost,D.J. ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research 2007; 13(-9-):2728-2737. >>> ABT-888; Saline; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; dose-response (pg 2732, fig. 2); cancer; animal info (C57BL/6, SCID); chemotherapeutic; "ABT-888 administered... via (minipump) not only potentiated cyclophosphamide... but also caused tumor regression, whereas the cyclophosphamide monotherapy only slightly delayed tumor growth." pg 2733.

P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor; half-life (pg 1894) "<2h in the mouse" 6.1h in larger animals.

P8456 Garbaccio,R.M., Tasbera,E.S., Neilson,L.A., Coleman,P.J., Fraley,M.E., Olson,C., Bergman,J., Torrent,M., Buser,C.A., Rickert,K., Walsh,E.S., Hamilton,K., Lobell,R.B., Tao,W.K., South,V.J., Diehl,R.E., Davide,J.P., Yan,Y.W., Kuo,L.C., Li,C.Z., Prueksaritanont,T., Fernandez-Metzler,C., Mahan,E.A., Slaughter,D.E., Salata,J.J., Kohl,N.E., Huber,H.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. BIOORGANIC&MEDICINAL CHEMISTRY LETTERS 2007; 17(-20-):5671-5676. >>> Kinesin spindle protein inhibitor; SC; Mice (nude); 2001D; 22-24 hours; Cancer (ovarian carcinoma); animal info (athymic nude).

P8514 Ishikawa,M., Kitayama,J., Yamauchi,T., Kadowaki,T., Maki,T., Miyato,H., Yamashita,H., Nagawa,H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. CANCER SCIENCE 2007; 98(-7-):1120-1127. >>> Adiponectin, recomb. mouse; PBS; IP; Mice (nude); 2004; 14 days; Controls received mp w/ vehicle; comparison of intratumoral injections vs. mp; no stress (see pg. 1124); cancer (gastric); peptides; animal info (female, BALB/c, nude, 5 weeks old); "Continuous adiponectin infusion into the peritoneal cavity caused significant antitumor effects." (p. 1126); "The intraperitoneal infusion did not cause apparent side effects with no significant change of total weight." (p. 1124).

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8729 Masunaga,S., Takahashi,A., Ohnishi,K., Nagata,K., Suzuki,M., Kashino,G., Kinashi,Y., Ohnishi,T., Ono,K. Dependency of repair of radiation-induced damage on p53 status and efficient inhibition of the repair with wortmannin treatment in vivo, with reference to the effect on intratumor quiescent cell population. Oncology Reports 2007; 18(-6-):1589-1596. >>> Uridine, bromodeoxy-; Saline; SC; Mice (nude); 2001; 7 days; Tissue perfusion (tumor); cancer; animal info (Balb/cA, nude); labeling of tumor cells.

P8224 Menon,J., Soto-Pantoja,D.R., Callahan,M.F., Cline,J.M., Ferrario,C.M., Tallant,E.A., Gallagher,P.E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007; 67(-6-):2809-2815. >>> Angiotensin (1-7); Saline; heparin; IV (jugular); Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 2810); cancer (lung); peptides; animal info (male, athymic, 2-4 weeks old, 15-20 grams); "During the infusion period, the animals maintained their body weight as well as food and water consumption and showed no evidence of reduced motor function. Additionally, no gross pathological abnormalities were observed in major organs..indicating a lack of toxic side effects." (p. 2810).

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

P8305 Mook,O.R., Baas,F., de Wissel,M.B., Fluiter,K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS 2007; 6(-3-):833-843. >>> RNA, small interfering; RNA, small interfering, LNA-modified; Radio-isotopes, 3H-; SC; Mice (nude); 1007D; 7 days; 48 hours; Controls received mp w/ mismatch siRNA or saline; comparison of IV injections vs. mp; stability verified by incubation in mouse serum; half-life (p. 837) increased in LNA-modified; unmodified completely degraded in<5 hours; cancer (pancreatic); animal info (NMRI nu/nu, 8-10 weeks old); siRNA against RNA polymerase II, enhanced GFP, or mismatch.

P8489 Song,P., Sekhon,H.S., Lu,A., Arredondo,J., Sauer,D., Gravett,C., Mark,G.P., Grando,S.A., Spindel,E.R. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Research 2007; 67(-8-):3936-3944. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; plasma levels taken; dose-response (p. 3941); cancer (lung); tumors implanted in right flank; M3 receptor antagonist; xenograft; animal info (6-7 weeks old).

P8704 Tummalapalli,P., Spomar,D., Gondi,C.S., Olivero,W.C., Gujrati,M., Dinh,D.H., Rao,J.S. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 31(-5-):1039-1050. >>> RNA, small interfering; Mice (nude); 3-4 weeks; Controls received no treatment; cancer (meningioma); animal info (athymic, nude); siRNA plasmid vectors targeting cathepsin B and matrix metalloproteinase MMP9.

P8925 Ye,L., Lewis-Russell,J.M., Davies,G., Sanders,A.J., Kynaston,H., Jiang,W.G. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(-2-):521-529. >>> Hepatocyte growth factor, recomb. human; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ BSA buffer; cancer (prostate); peptides; animal info (female, athymic, nude, CD-1, 4-6 wks old); HGF antagonist.

P8467 Zhang,Y.M., Bressler,J.P., Neal,J., Lal,B., Bhang,H.E.C., Laterra,J., Pomper,M.G. ABCG2/BCRP expression modulates D-luciferin-based bioluminescence imaging. Cancer Research 2007; 67(-19-):9389-9397. >>> Luciferin; SC; Mice (nude); 1007D; 1 hour; Cancer; bioluminescence imaging (BLI); animal info (female, nude, 6 wks old); tumor cells injected SC; cancer (HEK 293); peptides; pg 939s shows images with pumps implanted; IVIS 200 bioluminescence.

R0238 Boeckle,S., Wagner,E. Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS Journal 2006; 8(-4-):E731-E742. >>> Virus, synthetic RNA; Intratumoral; Mice (nude); ; Cancer (glioblastoma); "Control animals within 30 days after tumor implantation, all treated animals survived for >1 year and were completely cured." (p. E738); gene therapy.

P8121 Fujii,T., Yonemitsu,Y., Onimaru,M., Tanii,M., Nakano,T., Egashira,K., Takehara,T., Inoue,M., Hasegawa,M., Kuwano,H., Sueishi,K. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2- mediated therapeutic neovascularization - Critical role of the inflammatory/arteriogenic pathway. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2006; 26(-11-):2483-2489. >>> Antibody, anti-VEGF; IP; Mice (nude); 1007D; ; Controls received mp w/ IgG; cardiovascular; ischemia (hind limb); animal info (male, C57BL/6, 6-7 wk. old; Balb/c nu/nu, 5 wk. old; C57BL/6, CCR2-/-).

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.

P8140 Husen,B., Huhtinen,K., Saloniemi,T., Messinger,J., Thole,H.H., Poutanen,M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006; 147(-11-):5333-5339. >>> B10721325; estrone; DMSO; propanediol; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (p.5335); pumps replaced after 14 days; enzyme inhibitor (hydroxysteroid 17 beta dehydrogenase 1); cancer (breast); animal info (female, BALB/cA Bom-v, Crl: nu/nu, 10-11 wks old); 50%DMSO; endocrinology.

P7807 Jung,F.H., Pasquet,G., Lambert-van der Brempt,C., Lohmann,J.J.M., Warin,N., Renaud,F., Germain,H., De Savi,C., Roberts,N., Johnson,T., Dousson,C., Hill,G.B., Mortlock,A.A., Heron,N., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Green,S., Brown,E., Thompson,K., Brightwell,S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006; 49(-3-):955-970. >>> Thiazoloquinazoline, compound 54; Tris buffer; SC; Mice (nude); 2001D; 48 hours; Controls received mp w/ vehicle; half-life (pg. 963) 0.7 hours in mouse plasma; enzyme inhibitor (aurora A/B kinase); cancer (colorectal carcinoma); animal info (Swiss nu/nu, male, 8-10 wk old).

P7877 Kaneko,H., Kikuchi,K., Noguchi,J., Ozawa,M., Ohnuma,K., Maedomari,N., Kashiwazaki,N. Effects of gonadotrophin treatments on meiotic and developmental competence of oocytes in porcine primordial follicles following xenografting to nude mice. REPRODUCTION 2006; 131(-2-):279-288. >>> Follicle-stimulating hormone, porcine; Saline; SC; Mice (nude); 2004; 7, 14 days; Controls received no hormone treatment; replacement therapy (ovariectomy); dose-response (pg. 280); animal info (female, Crlj: CD1-Foxn1nu, 5-6 wk old); ovarian xenografts.

P8018 Kim,K.S., Sengupta,S., Berk,M., Kwak,Y.G., Escobar,P.F., Belinson,J., Mok,S.C., Xu,Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Research 2006; 66(-16-):7983-7990. >>> Lysophosphatidic acid; PBS; IP; Mice (nude); 1002; 21 days; Controls received mp w/ vehicle; pumps replaced every 15 days; cancer (ovarian carcinoma); animal info (female, nu/nu, skov3 tumors placed on ovaries); mp siliconized by placing 100 ul sigmacote into mp, removing liquid and letting the mp dry before agent is introduced; developed mouse model of metastatic ovarian cancer.

P8991 Liu,X.D., Fridman,J.S., Wang,Q., Caulder,E., Yang,G.J., Covington,M., Liu,C., Marando,C., Zhuo,J.C., Li,Y.L., Yao,W., Vaddi,K., Newton,R.C., Scherle,P.A., Friedman,S.M. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. CANCER BIOLOGY&THERAPY 2006; 5(-6-):648-656. >>> INCB003619; DMSO; SC; Mice (nude); 6, 28 days; Controls received mp w/ vehicle; functionality of mp verified by plasma INCB003619 levels; dose-response (fig. 5); enzyme inhibitor (ADAM protease); cancer (breast); animal info (female, athymic, CD-1, nu/nu, 7-8 wks old).

P8208 Martens,T., Schmidt,N.O., Eckerich,C., Fillbrandt,R., Merchant,M., Schwall,R., Westphal,M., Lamszus,K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clinical Cancer Research 2006; 12(-20-):6144-6152. >>> Antibody, anti-c-Met, OA5D5; Histidine; CSF/CNS (intratumoral); Mice (nude); 2004; 12, 21, 28 days; Controls received mp w/ vehicle; cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (male, NMRI-nu/nu, 6-8 wks old); "Because the OA-5D5 antibody is a relatively large but stable molecule, convection-enhanced drug delivery (by mp) was ideally suited to deliver it in our orthotopic model." (p.6151); tissue perfusion (tumor).

P8169 Masunaga,S.I., Uto,Y., Nagasawa,H., Hori,H., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer Research 2006; 26(-2A-):1261-1270. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice (nude); 5, 7 days; Cancer (squamous cell carcinoma); animal info (BALB/cA, C3H/He, 6-7 weeks old, 22 grams); labeling of tumor 'P' cells.

P7694 Michl,J., Scharf,B., Schmidt,A., Huynh,C. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer 2006; 119(-7-):1577-1585. >>> PNC-28; PBS, sterile; SC; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ control peptide; cancer (pancreatic); peptides; animal info (Nu/Nu, 7-8 weeks old, 22-24 g); xenotransplant tumor cells in hindleg or IP; additional mice had IP pumps; "...PNC-28 may be effective in treating cancers especially if delivered directly to the tumor." (p. 1577).

P7623 Ohyama,M., Terunuma,A., Tock,C.L., Radonovich,M.F., Pise-Masison,C.A., Hopping,S.B., Brady,J.N., Udey,M.C., Vogel,J.C. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. Journal of Clinical Investigation 2006; 116(-1-):249-260. >>> Uridine, bromodeoxy-; SC; Mice (nude); 1002; 4-6 weeks; Pumps replaced every 2 weeks; multiple pumps per animal (2).

P7800 Palm,D., Lang,K., Niggemann,B., Drell,T.L., Masur,K., Zaenker,K.S., Entschladen,F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. International Journal of Cancer 2006; 118(-11-):2744-2749. >>> Norepinephrine; propranolol; Saline, physiological; ascorbic acid; SC; Mice (nude); 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; half-life (pg. 2745) short, quickly metabolized; cancer (prostate carcinoma); animal info (female, BALB/C nude, athymic, 6 wk. old, 15g.).

P7922 Segrelles,C., Moral,M., Lara,M.F., Ruiz,S., Santos,M., Leis,H., Garcia-Escudero,R., Martinez-Cruz,A.B., Martinez-Palacio,J., Hernandez,P., Ballestin,C., Paramio,J.M. Molecular determinants of Akt-induced keratinocyte transformation. ONCOGENE 2006; 25(-8-):1174-1185. >>> Rapamycin; PBS; BSA; SC; Mice (nude); 2002; 2 weeks; Cancer; animal info (nude, 5-6 weeks old, female).

P7999 Ueda,S., Nakamura,T., Yamada,A., Teratani,A., Matsui,N., Furukawa,S., Hoshino,Y., Narita,M., Yodoi,J., Nakamura,H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. LIFE SCIENCES 2006; 79(-12-):1170-1177. >>> Thioredoxin, human recomb.; SC; Mice (nude); 2002; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (colon, carcinoma); peptides; animal info (female, 6 weeks old, nude); xenograft.

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8286 Ying,H., Biroc,S.L., Li,W.W., Alicke,B., Xuan,J.A., Pagila,R., Ohashi,Y., Okada,T., Kamata,Y., Dinter,H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. MOLECULAR CANCER THERAPEUTICS 2006; 5(-9-):2158-2164. >>> Fasudil; Saline; SC; Mice (nude); 21 days; Controls received mp w/ vehicle; cancer (lung); enzyme inhibitor (rho kinase).